Skip to main content

Advertisement

Table 1 Baseline characteristics according to consolidation compliance

From: Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma

Characteristic Baseline characteristics Consolidation treatment
414 None received
118 (28.50 %)
Received
296 (71.50 %)
P
Age (years)   Mean (SD) Mean (SD) Mean (SD)  
56.00 (7.21) 57.08 (6.48) 55.57 (7.44) 0.07
Median (IQR) Median (IQR) Median (IQR)
57.47 (51.57–61.74) 58.23 (52.40–62.28) 56.76 (51.08–61.49)
Sex Male 236 (57.00 %) 62 (52.54 %) 174 (58.78 %) 0.25
Female 178 (43.00 %) 56 (47.46 %) 122 (41.22 %)
Haemoglobin (g/dL) >10.5 normal 251 (60.63 %) 67 (56.78 %) 184 (62.16 %) 0.31
≤10.5 abnormal 163 (39.37 %) 51 (43.22 %) 112 (37.84 %)
Platelets (×109 per L) >150 normal 369 (89.13 %) 107 (90.68 %) 262 (88.51 %) 0.52
≤150 abnormal 45 (10.87 %) 11 (9.32 %) 34 (11.49 %)
Creatinine (μmol/dL) ≤1.2 normal 326 (78.74 %) 94 (79.66 %) 232 (78.38 %) 0.77
>1.2 abnormal 88 (21.26 %) 24 (20.34 %) 64 (21.62 %)
LDH (U/L) ≤190 normal 59 (14.25 %) 24 (20.34 %) 35 (11.82 %) 0.03
>190 abnormal 355 (85.75 %) 94 (79.66 %) 261 (88.18 %)
ISS stage 1 180 (43.48 %) 44 (37.29 %) 136 (45.95 %) 0.26
2 162 (39.13 %) 50 (42.37 %) 112 (37.84 %)
3 72 (17.39 %) 24 (20.34 %) 48 (16.22 %)
IgA isotype IgA 81 (19.57 %) 25 (21.19 %) 56 (18.92 %) 0.60
Not IgA 333 (80.43 %) 93 (78.81 %) 240 (81.08 %)
Del(13q) absent 214 (51.69 %) 61 (51.69 %) 153 (51.69 %) 0.99
present 200 (48.31 %) 57 (48.31 %) 143 (48.31 %)
Del(17p) absent 385 (93.00 %) 110 (93.22 %) 275 (92.91 %) 0.91
present 29 (7.00 %) 8 (6.78 %) 21 (7.09 %)
T(4;14) absent 331 (79.95 %) 98 (83.05 %) 233 (78.72 %) 0.32
present 83 (20.05 %) 20 (16.95 %) 63 (21.28 %)
Treatment arm A experimental 200 (48.31 %) 53 (44.92 %) 147 (49.66 %) 0.38
B control 214 (51.69 %) 65 (55.08 %) 149 (50.34 %)
  1. Wilcoxon-Mann-Whitney test was used for continuous variables
  2. Chi square test was used for categorical variables